Compare
Lucid Diagnostics Inc. vs Picard Medical, Inc. vs Cerenome, Inc. vs Tenon Medical, Inc.
| Latest fiscal year | Lucid Diagnostics Inc. LUCD | Picard Medical, Inc. PMI | Cerenome, Inc. CNSY | Tenon Medical, Inc. TNON |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.71M | $4.94M | $5.21M | $3.94M |
| Revenue growth (YoY) | +8.3% | +12.5% | -10.5% | +20.4% |
| Gross margin | -41.7% (computed) | -4.1% | n/a | 59.8% |
| Operating margin | n/m | -268.4% | -293.5% | -324.3% |
| Net margin | n/m | -546.6% | -429.4% | -318.4% |
| Net income | -$58.01M | -$27.00M | -$22.39M | -$12.56M |
| EPS (Diluted) | n/a | n/a | -$0.29 | -$1.70 |
| Operating cash flow | -$46.48M | -$15.67M | -$20.77M | -$10.74M |
| Free cash flow | -$46.68M | n/a | -$20.84M | -$11.02M |
| Cash & equivalents | n/a | $7.45M | $4.26M | $3.76M |
| Total assets | $40.45M | $22.55M | $16.32M | $10.76M |
| Total liabilities | $29.51M | $18.76M | $12.33M | $5.72M |
| Shareholders' equity | $10.94M | $3.79M | $4.00M | $5.04M |
| Return on year-end equity | -530.4% | -712.6% | -560.2% | -249.1% |
| Shares outstanding | 131.10M | 73.70M | 138.68M | 10.85M |
Revenue, most recent five fiscal years
| Fiscal year | Lucid Diagnostics Inc. | Picard Medical, Inc. | Cerenome, Inc. | Tenon Medical, Inc. |
|---|---|---|---|---|
| Latest | $4.71M Ended 2025-12-31 | $4.94M Ended 2025-12-31 | $5.21M Ended 2025-12-31 | $3.94M Ended 2025-12-31 |
| 1 year earlier | $4.35M Ended 2024-12-31 | $4.39M Ended 2024-12-31 | $5.82M Ended 2024-12-31 | $3.28M Ended 2024-12-31 |
| 2 years earlier | $2.43M Ended 2023-12-31 | n/a | $4.91M Ended 2023-12-31 | $2.93M Ended 2023-12-31 |
| 3 years earlier | $377.0K Ended 2022-12-31 | n/a | n/a | $691.0K Ended 2022-12-31 |
| 4 years earlier | $500.0K Ended 2021-12-31 | n/a | n/a | $160.0K Ended 2021-12-31 |